GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology. Dr. Keating will lead clinical development of GigaGen’s recombinant hyperimmune gammaglobulin product in collaboration with pharmaceutical partner Grifols. 

Read the full press release.